Amerisafe (AMSF) Stock Faces Margin Pressure As Q2 Combined Ratio of 95.4% Tests Bull Case

AMERISAFE (AMSF) opened Q2 2026 with total revenue of US$92 million and basic EPS of US$0.79, alongside net income of US$14.6 million that frames the quarter as a clean snapshot of its underwriting and investment performance. The company has seen quarterly revenue move from US$81.1 million in Q2 2025 to US$92 million in Q2 2026, while basic EPS across the same quarters shifted from US$0.73 to US$0.79, setting up a picture of how the top and bottom lines have tracked through the current pricing and claims cycle. With a Q2 combined ratio of 95.4%, the latest numbers put margins and underwriting discipline at the center of how investors are likely to read this earnings release.

See our full analysis for AMERISAFE.

With the headline figures set, the next step is to line up AMERISAFE’s recent results against the strongest narratives in the market to see which story threads are supported by the numbers and which ones start to look out of date.

See what the community is saying about AMERISAFE

Combined ratio at 95.4% puts pressure on AMERISAFE margins

• The Q2 2026 combined ratio of 95.4% compares with 93.2% in Q1 2026 and 90.6% in Q3 2025, while the latest trailing net profit margin sits at 14%, down from 16.5% a year earlier.
• Consensus narrative highlights strong renewal retention and disciplined risk selection as supports for long term underwriting margins. However, the upward move in the combined ratio and lower trailing margin suggest rising medical severity and higher expense ratios are feeding through to profitability.
  • Industry data in the narratives points to medical severity rising about 6% recently, which lines up with the softer 14% net margin and higher 95.4% combined ratio that investors will watch closely.
  • At the same time, expense ratios referenced at 31.3% versus 29.8% previously indicate that investment in growth and assessments is adding to costs even as revenue growth on a trailing basis is 2.3% per year.

Revenue and EPS trends versus bearish earnings concerns

• On a trailing 12 month basis, AMERISAFE reports revenue of US$335.7 million and net income of US$47.0 million, while Basic EPS is US$2.50 compared with the 5 year earnings trend that declined about 9.4% per year.
• Bears argue that earnings are set to decline about 16% per year over the next three years. The current trailing figures and Q2 EPS of about US$0.79 show earnings still supported by US$91.97 million in quarterly revenue and workers' compensation specialization.
  • The bearish narrative expects earnings to move to about US$31.4 million by 2029, whereas the most recent trailing net income of US$47.0 million shows the starting point for any decline is materially higher than that future estimate.
  • With revenue growth running at roughly 2.3% per year on a trailing basis, the cautious view that premium growth may be constrained by automation and demographic shifts is not directly visible in the latest reported revenue level, so investors may focus on how quickly that 2.3% pace changes from here.

For readers weighing how these earnings stack up against the more cautious long term projections bears are using, it helps to see their full thesis set out in one place, including the assumptions on margins, automation, and medical cost trends that sit behind it 🐻 AMERISAFE Bear Case.

DCF fair value and P/E put AMERISAFE’s pricing in context

• With the share price at US$31.15, the stock screens at a P/E of 12.4x, which matches the US insurance industry average of 12.4x and sits above the cited peer average of 8.2x, while the supplied DCF fair value of about US$59.37 is well above the current price.
• Bullish investors point to the DCF fair value of US$59.37 and bullish revenue assumptions of 5.2% annual growth as evidence that the current price leaves room for upside. At the same time, the bullish narrative also expects margins to contract from about 14.3% to 9.1% and earnings to fall to about US$34.3 million, which creates a tension between lower earnings and a higher implied valuation multiple.
  • To reach a price target of US$35.00 under the bullish scenario, the stock would need to trade at a higher multiple than the current 12.4x P/E, despite the forward margin compression that those optimistic forecasts are already building in.
  • Because the trailing dividend yield of 8.48% is not well covered by free cash flow, any bullish case that leans heavily on the high yield as part of total return needs to grapple with the cash coverage pressure highlighted in the trailing 12 month analysis.

If you want to see how bullish investors connect these valuation gaps with AMERISAFE’s underwriting track record and premium growth assumptions, it is worth reading their case in full 🐂 AMERISAFE Bull Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for AMERISAFE on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

After weighing both the bullish and bearish narratives around AMERISAFE, the real question is how the current data lines up with your own expectations. Take a close look at the reported figures, pressure test the assumptions in each story, and then balance the identified risks and rewards using the 1 key reward and 2 important warning signs.

See What Else Is Out There Beyond AMERISAFE

AMERISAFE’s higher combined ratio, softer trailing net margin, and dividend that is not well covered by free cash flow all point to pressure on profitability.

If you want stocks where income potential lines up more cleanly with cash support right now, compare AMERISAFE’s profile against the 7 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com